Lorlatinib in ALK- and ROS1-rearranged metastatic non-small-cell lung cancer: a Russian multicentre real-world study (ESMO Asia 2026) - Oct 1, 2026 - Abstract #1030eP; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Clinical • Metastases • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • ROS1
|
|
Sergei A. Smolin; Basir Bammatov; Muradin Thakohov; Polina Feoktistova; Egvenia Khatkova; Elizaveta O. Chuykova; Ekaterina A. Parfenova; Lyudmila Zhukova
|